Outcomes of Drug Interactions Between Antiretrovirals and Co-Medications, Including Over-the-Counter Drugs : A Real-World Study
Ambrosioni, Juan (Universitat de Barcelona)
Díaz, Natalia Anahí (Infectious Diseases Service. Hospital Mariano y Luciano de La Vega (Argentina))
Marzolini, Catia (University of Liverpool)
Dragovic, Gordana (University of Belgrade)
Imaz, Arkaitz (Universitat de Barcelona)
Calcagno, Andrea (Hospital del Mar (Barcelona, Catalunya))
Curran, Adrian (Vall d'Hebron Institut de Recerca (VHIR))
Troya, Jesús (Hospital Universitario Infanta Leonor)
Tuset, Montse (Hospital Clínic i Provincial de Barcelona)
Khoo, Saye (University of Liverpool)
Burger, David (Radboud Institute for Medical Innovation (Holanda))
Cortés, Claudia P. (Universidad de Chile)
Naous, Nadia (Chelsea and Westminster Hospital NHS Foundation Trust)
Moltó, José (Instituto de Salud Carlos III)

Data:	2024
Resum:	Introduction: The objective was to characterize real-world outcomes of drug-drug interactions (DDIs) between antiretrovirals (ARVs) and other drugs, including over-the-counter medications (OTC), and treatment outcomes in clinical practice. Methods: www. clinicalcasesDDIs. com is an open-access website for healthcare providers to consult and briefly describe real-world clinical cases on DDI with ARVs. We reviewed all the clinical cases reported to the website between March 2019 and May 2023. Results: A total of 139 cases were reported, mostly involving ritonavir or cobicistat (boosters; 74 cases), unboosted integrase inhibitors (InSTI; 29 cases), and non-nucleoside reverse transcriptase inhibitors (NNRTI; 23 cases). Central nervous system drugs (29 cases) and cardiovascular drugs (19 cases) were the most frequently described co-medications. Notably, OTC medications were implicated in 27 cases, including mineral supplements (11 cases), herbals (8 cases), weight loss drugs (4 cases), anabolic steroids (3 cases), and recreational drugs (1 case). OTC acted as the perpetrator drug in 21 cases, leading to loss of ARV efficacy in 17 instances (mineral supplements in 10 cases, weight loss drugs in 4 cases, herbals in 3 cases). Additionally, toxicity was reported in 4 out of 6 cases where OTC was considered the victim drug of the DDI (anabolic steroids in 3 cases, MDMA in 1 case). Conclusions: Frequent unwanted outcomes resulting from DDIs between ARVs and OTC medications underscore the importance of integrating non-prescription drugs into medication reconciliation. The real-world data available through www. clinicalcasesDDIs. com serves as a valuable resource for assessing the clinical relevance of DDIs.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	HIV infection ; Drug interactions ; Over-the-counter medications ; Real-life clinical cases
Publicat a:	Infectious Diseases and Therapy, Vol. 13 Núm. 3 (march 2024) , p. 609-617, ISSN 2193-6382

DOI: 10.1007/s40121-024-00935-0
PMID: 38372897

9 p, 287.8 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats